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634Objective: Apical hypertrophic cardiomyopathy is a morphologic variant in which the hypertrophy is primarily
localized to the apex of the left ventricle. A subset of patients have progressive, drug-refractory diastolic heart
failure with severely limiting symptoms caused by low cardiac output. Heart transplantation has been the only
therapeutic option available for such patients. This study analyzes clinical and hemodynamic outcomes of a novel
surgical technique to improve diastolic filling by means of left ventricular cavity enlargement.
Methods: Forty-four symptomatic patients underwent apical myectomy to augment left ventricular end-diastolic
volume. Myectomy was performed through an apical incision, and hypertrophic muscle was excised at the apex
and midventricle. Information from a prospective database was supplemented by surveys, patient contact, and
medical records.
Results: The mean age of the patients was 50 17 years, and 66% were women. All patients were severely lim-
ited with dyspnea, 61% had angina, and 59% had syncope/presyncope. Ninety-one percent of patients were in
New York Heart Association class III or IV. A mean of 16 7 g of muscle was removed. Preoperative and post-
operative hemodynamic catheterization (n¼ 14) showed a decrease in left ventricular end-diastolic pressure from
28 9 to 24 7 mm Hg (P¼ .002) and an increase in end-diastolic volume index from 55 17 to 68 18 mL/
m2 (P ¼ .003). Invasive measurements of stroke volume increased from 56  17 to 63  19 mL (P ¼ .007). Of
the 42 patients who survived to hospital discharge, 41 had improvement in symptoms. Mean peak maximum
oxygen consumption with exercise (n ¼ 5) increased from 13.5  4.4 to 15.8  4.6 mL/kg per minute. Survival
at 1, 3, and 5 years was 95%, 81%, and 81%, respectively. At follow-up of 2.6  3.1 years, 23 (74%) patients
were in New York Heart Association class I or II. One patient underwent heart transplantation 5 years after apical
myectomy.
Conclusions: Apical myectomy improves functional status by decreasing left ventricular end-diastolic pressure,
improving operative compliance, and increasing stroke volume. This procedure might be of value in other patients
with hypertrophic cardiomyopathy who have severe hypertrophy and small left ventricular end-diastolic volume.
(J Thorac Cardiovasc Surg 2010;139:634-40)Apical hypertrophic cardiomyopathy (ApHCM) is a rare
morphologic variant of hypertrophic cardiomyopathy
(HCM), with the hypertrophy primarily localized in the
apex of the left ventricle (LV).1-6 Generally, ApHCM has
been considered a benign condition, with few or mild symp-
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The Journal of Thoracic and Cardiovascular SurgSome investigators, however, have reported a subset of
patients with symptoms of fatigue, angina, or dyspnea, and
still others with arrhythmia or even sudden death.2,3,11-13
Treatment options for symptomatic patients with ApHCM
are limited, and clinical experience has shown that response
to medical therapy is poorer than that for patients with
obstructive HCM.
In this report we describe our experience with a surgical
approach to the treatment of ApHCM that involves the exci-
sion of a portion of the thickened muscle to permit greater
filling of the LV in diastole. We evaluated hemodynamics,
including the effect of the procedure on left ventricular
end-diastolic volume (LVEDV), end-diastolic pressure,
and stroke volume (SV), and we assessed late patient sur-
vival and functional status.MATERIALS AND METHODS
After approval of the institutional review board, we reviewed the clinical,
hemodynamic, and imaging data of 45 patients with ApHCM who hadery c March 2010
FIGURE 2. Cardiac magnetic resonance imaging demonstrates apical
hypertrophic cardiomyopathy during diastole before (A) and after (B) apical
myectomy that substantially enlarged the left ventricular cavity.
Abbreviations and Acronyms
ApHCM ¼ apical hypertrophic cardiomyopathy
HCM ¼ hypertrophic cardiomyopathy
ICD ¼ implantable cardioverter defibrillator
LV ¼ left ventricle
LVEDV ¼ left ventricular end-diastolic volume
MRI ¼ magnetic resonance imaging
NYHA ¼ New York Heart Association
PPM ¼ permanent pacemaker
SV ¼ stroke volume
VO2max ¼ peak oxygen consumption
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tween September 1993 and January 2009. One patient who refused research
authorization was excluded from analysis. Diagnostic studies were per-
formed as clinically indicated and evolved during this 15-year experience.
The diagnosis of ApHCMwas established in all patients by means of trans-
thoracic echocardiographic analysis, which demonstrated localized hyper-
trophy at the apical and middle levels of the LV. Additional preoperative
testing included exercise testing with measurement of peak oxygen con-
sumption (VO2max), LV pressure measurements with high-fidelity manom-
eter-tipped catheters (Figure 1), and simultaneous left ventriculographic
analysis; more recently, magnetic resonance imaging (MRI) was conducted,
including measurement of LV volumes in select patients (Figure 2).
Operations were performed through a standard median sternotomy. Pa-
tients were started on cardiopulmonary bypass (normothermia at 2.4 L $
min1 $ m2) by using direct aortic cannulation and a single 2-stage venous
cannula. Cold antegrade blood cardioplegia (1000–1200 mL) was used for
myocardial protection. In each patient an apical ventriculotomy was made
lateral to the left anterior descending artery (Figure 3). The apex of the heart
was obliterated with muscle, and initial myectomy was performed along the
septum. After identification of the anterolateral and posteromedial papillary
muscles, myectomy was extended to other areas with the goal of enlarging
the apical third of the LV. The ventricular cavity was also augmented by
means of division of hypertrophied trabeculae and, in some patients, by
means of careful shaving of the hypertrophied papillary muscles. The resec-0
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FIGURE 1. Pressure–volume loops in a patient with apical hypertrophic
cardiomyopathy before (A) and after (B) surgical intervention. Pressure
recordings were taken with high-fidelity micromanometer catheters (Millar
Instruments, Houston, Tex); left ventricular volumes were calculated from
contrast ventriculograms. Apical myectomy resulted in an increase in stroke
volume (SV) and a larger left ventricular end-diastolic volume at lower end-
diastolic pressure (EDP), suggesting improved left ventricular compliance
after the operation. Preop, Preoperatively; Postop, postoperatively.
The Journal of Thoracic and Cation removed the mass of myocardium filling the apex of the heart, leaving
a wall thickness of 10 to 12 mm. After resection, the apical ventriculotomy
was closed in 2 layers over strips of felt. In 7 patients additional muscle was
removed from the LV outflow tract through the aortic valve after an aortot-
omy. Other concomitant procedures were performed as indicated.
Patients underwent transthoracic echocardiographic analysis, hemody-
namic cardiac catheterization, or MRI before hospital dismissal and at
late follow-up, as clinically indicated. Patients’ records were reviewed for
available follow-up information. In addition, patients were contacted
through survey follow-up, and vital status was confirmed by using Accurint
(LexisNexis, New York, NY [www.accurint.com]).
Statistics were performed with SAS statistical software (SAS Institute,
Inc, Cary, NC). Results for continuous data are reported as means  stan-
dard deviations or medians and ranges, as appropriate, and results for cate-
gorical data are reported as numbers (percentages) for each category from
the observed total. Paired t tests were used to compare continuous parame-
ters between preoperative, dismissal, and late hemodynamic measurements.
Kaplan–Meier survival methods were used to assess mortality.RESULTS
Forty-four patients underwent apical myectomy between
September 1993 and January 2009. The mean age of the pa-
tients was 50  17 years, and 66% were women (Table 1).
All patients were symptomatic at the time of the operation
despite aggressive medical therapy. Systolic function was
preserved in all patients, and the mean ejection fractionrdiovascular Surgery c Volume 139, Number 3 635
FIGURE 3. A and B, An incisionmade in the apex of the left ventricle (A) reveals the extensive muscle in the apex (B). C,Myectomy is performed to remove
excess apical muscle. D, After myectomy, the incision is closed with felt strips.
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in all patients by means of echocardiographic, angiographic,
or MRI analysis; 7 patients also had evidence of subaortic
LV outflow tract obstruction. No clinically significant coro-
nary artery lesions requiring coronary artery bypass grafting
were identified on preoperative coronary angiograms, but 2
patients had myocardial bridging of the left anterior
descending artery.
Operative data are listed in Table 2. The mean mass of
muscle removed from the LV was 15.7  6.8 g. Concomi-
tant procedures included tricuspid valve repair or replace-
ment (n ¼ 3), closure of the left atrial appendage (n ¼ 4),
the maze procedure (n ¼ 3), repair of myocardial bridging
(n¼ 2), and mitral valve replacement (n¼ 1). Three patients
required intra-aortic balloon support early after the opera-
tion, and 2 (4.5%) patients died perioperatively. One death
was related to severe bleeding and subsequent multiorgan
failure. The second death occurred in a patient who had
thrombosis of her mitral valve prosthesis and required emer-
gency rereplacement. This second patient died as the result
of neurologic injury resulting from shock before reoperation.
All 44 patients had a Swan–Ganz catheter placed during
the operation, and 38 had complete hemodynamic measure-
ments taken, including right heart pressures and cardiac out-
put during anesthesia before sternal incision, at the time of
sternal closure, and before catheter removal and discharge
from the intensive care unit (Table 3).
Preoperative and early postoperative transthoracic echo-
cardiograms were available for 39 patients, and late echocar-
diograms were available for 21 patients a mean of 2.3  2.1
years after myectomy. In these 21 patients ejection fractions636 The Journal of Thoracic and Cardiovascular Surgdecreased from a mean of 72%  8% preoperatively to
64%  12% at dismissal and 61%  12% at last follow-
up (Figure 4). All patients had visible enlargement of the
LV cavity.
Eleven patients had both preoperative and predismissal
or late hemodynamic catheterization. The mean indexed
LVEDV increased from 55  17 to 68  18 mL/m2 (P ¼
.003), and the mean indexed SV increased from 39  17
to 46 13 mL/m2 (P¼ .002, Figure 5). The mean estimated
LV ejection fraction decreased on angiographic analysis
from 71%  8% to 65%  8% (P ¼ .06), whereas the
mean left ventricular end-diastolic pressure decreased from
28  9 to 24  6 mm Hg (P ¼ .007, Figure 6).
Preoperative and postoperative cardiac MRI were per-
formed in 9 patients. The mean LV end-diastolic indexed
volume increased by 13  16 mL/m2 (P ¼ .04), and the
mean indexed LV SV increased by 3  9 mL/m2 (P ¼ .02).
Five patients underwent preoperative and late postopera-
tive exercise testing with measurement of VO2max, as de-
scribed previously.12 The mean preoperative VO2max of
13.5  4.4 increased to 14.7  4.7 (P ¼ .004) at a median
follow-up of 6.7 months (range, 5–28 months).
Functional status was available in 33 (85%) of 39 alive
patients, all but 1 of whom had initial improvement in symp-
toms; at last follow-up (mean, 3.2 3.3 years), 23 (70%) of
these 33 patients were in New York Heart Association
(NYHA) class I or II. All 8 patients reportedly in NYHA
class III, and both of the patients in NYHA class IV had ini-
tial improvement in symptoms after the operation. The poor
residual functional status in the majority of patients was
believed to be due to either right heart failure, atrialery c March 2010
TABLE 1. Characteristics of 44 patients who underwent apical
myectomy
Characteristic No. (%)
Women 29 (66)
Race
White 33 (75)
Black 4 (9)
Middle Eastern 1 (2)
Not identified 6 (14)
NYHA class III or IV 40 (91)
Symptoms
Shortness of breath 44 (100)
Fatigue 44 (100)
Angina 27 (61)
Syncope or presyncope 26 (59)
Palpitations 18 (41)
History of arrhythmia
Atrial 17 (39)
Ventricular 5 (11)
Sinus rhythm 37 (84)
Pacemaker 4 (9)
ICD 9 (20)
Family history of HCM 10 (23)
Prior cardiac transplant
consultation
3 (7)
Medication
b-Blocker 31 (70)
Calcium-channel blocker 24 (55)
Angiotensin-converting
enzyme inhibitor
12 (27)
Diuretic 20 (45)
Other antiarrhythmic 9 (20)
NYHA, New York Heart Association; ICD, implantable cardioverter defibrillator;
HCM, hypertrophic cardiomyopathy.
TABLE 3. Measurement of stroke volume by using a Swan–Ganz
catheter in 38 patients who underwent apical myectomy
Time of measurement
Stroke volume
(mL)* P valuey
Before sternal split 55.6  17.0
At time of sternal closure 56.5  19.3 .74
Before ICU dismissal 62.7  19.0 .01
ICU, Intensive care unit. *Values are means standard deviations. yPvalues represent
a comparison with the measurement of stroke volume before sternal split.
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went cardiac transplantation 4.7 years after apical myec-
tomy. This patient had improvement in symptoms for 2
years after myectomy but subsequently had severe tricuspid
regurgitation and profound right heart failure caused by
a pacemaker lead. There were 2 late deaths (one from sudden
cardiac arrest). The only patient whose symptoms did not
improve after the operation died of unknown causes almost
3 years after the operation. Vital status was available at
a mean follow-up of 2.6  3.1 years (median, 1.3 years).TABLE 2. Operative characteristics of 44 patients who underwent
apical myectomy
Characteristic Value
Cardiopulmonary bypass time (min) 53.2  29.0
Crossclamp time (min) 32.7  17.9
Mitral valve repair or replacement, n (%) 6 (14)
Muscle mass removed (g) 15.7  6.8
Operative mortality, n (%) 2 (4.5)
Values are presented as means  standard deviations or numbers (percentages).
The Journal of Thoracic and CaSurvival at 1, 3, and 5 years was 95%, 81%, and 81%, re-
spectively (Figure 7).
Preoperatively, 4 patients had a permanent pacemaker
(PPM), and 9 patients had an implantable cardioverter defi-
brillator (ICD) placed. Five other patients received an ICD in
the perioperative period. In the follow-up period, 2 patients
received a PPM, and 1 patient received an ICD. The patient
who died of sudden cardiac arrest had neither a PPM nor an
ICD.
Thirteen patients required rehospitalization subsequent
to dismissal after the original procedure. Reasons for read-
mission included congestive heart failure (n ¼ 6), stroke
(n¼ 2), transient ischemic attack (n¼ 1), pulmonary embo-
lism (n ¼ 1), myocardial infarction (n ¼ 1), gastrointestinal
bleeding (n ¼ 1), and reoperation (n ¼ 1). The patient who
required reoperation had severe tricuspid valve regurgita-
tion. Heart failure persisted after tricuspid valve repair,
and the patient eventually required heart transplantation.DISCUSSION
Surgical treatment of patients with HCM consists mainly
of subaortic myectomy to relieve the LV outflow tract ob-
struction that occurs in as many as 70% of patients.14–18
Medical therapy with b-blockers, calcium-channel
blockers,14,15,17–20 or disopyramide21 might also reduce dy-
namic outflow gradients and improve symptoms in patientsFIGURE 4. Echocardiographic measurements of ejection fraction before
and after apical myectomy. Mean values are presented with standard devi-
ations. The P value was calculated for the change in mean ejection fraction.
rdiovascular Surgery c Volume 139, Number 3 637
FIGURE 5. A and B, Indexed left ventricular end-diastolic volume
(LVEDV; A) and indexed left ventricular (LV) stroke volume (B) in 11 pa-
tients who had both preoperative and postoperative hemodynamic catheter-
ization measurements. Mean values are presented with standard deviations.
The P value was calculated for the change in mean indexed LVEDV and the
change in indexed LV stroke volume.
FIGURE 7. Kaplan–Meier curve of survival of patients after operations for
apical hypertrophic cardiomyopathy.
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HCM is generally not associated with subaortic obstruction,
and symptoms, when present, respond poorly to medical
therapy.
This report is the first to describe outcomes for patients
treated with a novel surgical approach for ventricular remod-FIGURE 6. The change in left ventricular end-diastolic pressure (LVEDP)
on preoperative and postoperative hemodynamic catheterization. Mean
values are presented with standard deviations. The P value was calculated
for the change in mean LVEDP.
638 The Journal of Thoracic and Cardiovascular Surgeling in the management of symptomatic ApHCM. The pro-
cedure involves removal of hypertrophied muscle in the
apical and middle regions of the LV, thus creating a larger
chamber size in diastole. Although there might be mild
hypokinesis in the region of the apical incision, overall con-
tractility of the LV is preserved, with a resultant increase in
the effective operative compliance of the LV that allows
a larger filling volume without an increase in end-diastolic
pressure. Indeed, in our patients measured SV increased
after apical myectomy, and end-diastolic pressure was
reduced. This hemodynamic improvement was accompa-
nied by improvement in symptomatic status; all but 1 patient
noted some postsurgical relief of dyspnea.
Diastolic dysfunction in patients with HCM results from
a complex sequence of multiple interrelated events.17,22,23
Myocardial relaxation is impaired, as expected in any patient
with HCM. However, patients with ApHCM have an ana-
tomic limitation to diastolic filling. Severe hypertrophy at
the apical and middle portions of the ventricle results in
a small chamber size in the basal portion of the LV. The
small volume of this chamber, in addition to the increase
in muscle stiffness of the hypertrophied myocardium, results
in a major decrease in the effective operative compliance of
the LV.24
Traditional treatment options for symptomatic patients
with ApHCM have limited effectiveness. Medical therapy
with b-blockers, calcium-channel blockers, and angioten-
sin-converting enzyme inhibitors has been proposed to im-
prove LV diastolic filling.8,11 Although decreasing heart
rate and reducing LV afterload might offer some theoretic
benefit to hemodynamics and symptoms, most patients re-
main symptomatic or have symptom progression caused
by the noncompliant hypertrophied LV. Dual-chamber pac-
ing has not been effective in relieving symptoms in patients
without outflow tract obstruction.25 Heart transplantation is
the current treatment recommendation for patients withery c March 2010
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Dsevere refractory heart failure caused by nonobstructive
HCM, including the apical variant.26 In addition, severe
LV chamber hypertrophy might impede other surgical
adjuncts, such as the placement of an LV assist device.
There are no detailed studies on the natural history of
severely symptomatic patients with ApHCM. Indeed, most
patients with this HCM phenotype are considered to have
a benign prognosis, with good long-term survival and few
symptoms.6–9 Eriksson and colleagues11 evaluated late out-
comes for 105 patients with ApHCM and found a 15-year
survival rate of 95%, which is identical to that of an age-
matched and sex-matched cohort. With extended follow-
up, however, the survival rates of 87% at 20 years and
79% at 25 years after diagnosis were lower than expected.
In addition, some patients experienced fatigue, angina, dysp-
nea, arrhythmia, and even sudden death. Despite medical
therapy, 20% of patients deteriorated in functional class,
and 8 of the 105 patients progressed to NYHA class III or
IV during follow-up.11 These symptomatic patients have
no treatment options other than cardiac transplantation. In
fact, in our series 3 patients were initially referred to the
Mayo Clinic for evaluation for cardiac transplantation.
We observed no late complications from the apical inci-
sion used for myectomy and found no documented instances
of ventricular arrhythmias that originated from scarring in
this area. Ventricular tachycardia and sudden cardiac death
are, however, associated with this form of HCM, and
patients should be evaluated for risk of sudden death and
for consideration of an ICD.12,13 The incisions were usually
5 to 6 cm in length and situated at the apex of the LV, which
is nonfunctional in patients with ApHCM. These incisions
are smaller than those used for aneurysm repair or for other
ventricular restoration procedures.
In addition to removal of an adequate volume of muscle,
the procedure must avoid injury to the papillary muscles,
which are displaced apically in patients with ApHCM. A
limited initial ventriculotomy should first be made, and the
anterolateral and posteromedial papillary muscles should
be carefully identified before removal of large portions of
myocardium. As the myectomy proceeds with removal of
hypertrophied muscle from the apex, the enlarged papillary
muscles can be shaved to further increase LV volume and to
minimize the chance of residual midventricular obstruction.
Accurate assessment of the distribution of ventricular hy-
pertrophy and LVEDV is critical to the identification of pa-
tients who might be helped by apical myectomy. The low
normal (normal value, 30–50 mL/m2) preoperative SV of
our patients improved to a normal value postoperatively
(mean, 46 mL/m2); however, accuracy of volume assess-
ment by any imaging study is limited by the abnormally
shaped LV in patients with ApHCM. There are no com-
monly available validated corrections for imaging calcula-
tions of ventricular volume in patients with predominantly
apical LV hypertrophy.The Journal of Thoracic and CaSome limitations of our findings should be mentioned.
Detailed hemodynamic data were not available for all pa-
tients, and tests were performed as clinically indicated rather
than per a study protocol. Early in this series, ventricular
morphology was assessed by means of contrast ventriculo-
graphic analysis in some patients and by means of contrast
echocardiographic analysis in select others; more recently,
patients have had cardiac MRI to visualize the ventricular
anatomy, but this imaging technique cannot be used in all
patients for many reasons, including the presence of im-
plantable devices. We further recognize that confounding
factors, including a placebo effect, might have contributed
to the improvement in symptoms we noted in our patients.
Nevertheless, all but 1 patient had initial improvement in
symptoms that lasted as long as 11 years, and only 1 patient
had a progression of symptoms severe enough to warrant
heart transplantation during the follow-up period.CONCLUSIONS
A subset of patients with ApHCM present with severe
limiting symptoms of dyspnea and fatigue caused by dia-
stolic dysfunction and low cardiac output. Transapical ven-
tricular myectomy to increase LVEDV improves diastolic
function and SV. For patients with ApHCM who have lim-
iting symptoms despite optimal medical treatment, this new
procedure might be of benefit by improving hemodynamics
and ameliorating symptoms.References
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Dr Nicholas G. Smedira (Cleveland, Ohio). I have no dis-
closures. Dr Schaff, as usual, your presentation was clear and
very informative, and I want to congratulate you on outstanding
results. My first question relates to whether we are underesti-
mating the prevalence of this disorder? We were taught 10
years ago that the incidence of obstruction in patients with hy-
pertrophic obstructive cardiomyopathy was around 25%. We
now know that with provocative maneuvers, it is as high as
75%. Are there more patients out there with this disorder
than we are appreciating?
The second question relates to midcavitary obstruction, which
you briefly described in the article. Do you require a specific640 The Journal of Thoracic and Cardiovascular Surggradient by your imaging study to identify those patients you would
operate on, or do all these patients have a resting gradient, and if there
is not a resting gradient, do you do provocative maneuvers, such as
amyl nitrate, as we do with standard outflow tract obstruction?
You briefly mentioned that 30% of the patients had a decrease in
functional status over 5 years, and in the article this was related to
atrial arrhythmias and right ventricular dysfunction. Therefore I
have a 2-part question. I have been very aggressive when treating
atrial arrhythmias in patients who have hypertrophic obstructive
cardiomyopathy. Are you more aggressive doing some ablative
procedure in this cohort of patients? If you see a patient who has
symptoms of right ventricular failure, would you now refer that pa-
tient directly to transplantation rather than the apical myectomy?
Thank you for this opportunity.
Dr Schaff. Your first question had to do with the prevalence of
ApHCM. In our institution this subtype accounts for approximately
8% of the patients who come through the HCM clinic. There might
be other patients with HCM and small cavities who might benefit
from enlarging their ventricles.
The second question had to do with midventricular obstruction.
It is important to recognize that you can access the midventricle
through the apex easily, and this should be considered if midven-
tricular obstruction remains after relief of subaortic obstruction.
The final question had to do with the development of atrial fibril-
lation, and we do combine maze procedures or pulmonary vein iso-
lation with subaortic myectomy in patients who have HCM and
troublesome atrial fibrillation. However, for patients who have
atrial arrhythmias but are not in continuous atrial fibrillation, we
are more conservative because prophylactic procedures can impair
atrial transport function.
Dr Smedira. What about the right ventricle, right ventricular
failure?
Dr Schaff. We do not have any special insights into indentifying
patients who might have right ventricular failure, and this is an
important issue.
Dr R. Duane Davis (Durham, NC). What do you think the true
incidence is? Do you use magnetic resonance at all for quantifica-
tion of and trying to determine where you think you will have
benefit?
Dr Schaff. Well, it is hard to knowwhat the true incidence is be-
yond the figures that I gave you. We do use cardiac magnetic res-
onance in these patients, but quantification of volumes is difficult
because of ventricular morphology. You can see the cavity quite
well, but most of the formulas to calculate ventricular volumes
are based on a ventricular shape that these patients do not possess.
It is important to develop or learn new methods for measuring ven-
tricular volume with magnetic resonance or other techniques be-
cause, in my view, that is the key to identifying the patients who
might benefit from this procedure.ery c March 2010
